Sanjiv Patel - 30 Jun 2025 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role: President and CEO, Director
Signature: /s/ Brian Adams, as Attorney-in-Fact
Issuer symbol: RLAY
Transactions as of: 30 Jun 2025
Net transactions value: +$14,700
Form type: 4
Filing time: 01 Jul 2025, 16:59:29 UTC
Previous filing: 24 Apr 2025
Next filing: 10 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Patel Sanjiv	President and CEO, Director	C/O RELAY THERAPEUTICS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE	/s/ Brian Adams, as Attorney-in-Fact	01 Jul 2025	0001816210

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RLAY	Common Stock	Award	$14,700	+5,000	+0.61%	$2.94	826,667	30 Jun 2025	Direct	F1, F2, F3
holding	RLAY	Common Stock						199,548	30 Jun 2025	By The Patel Family Irrevocable Trust of 2019	F4
holding	RLAY	Common Stock						687,355	30 Jun 2025	By The SSP Irrevocable Trust of 2020	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
F2	In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2025.
F3	Includes 410,560 shares underlying RSUs.
F4	These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.